J&J Opens San Francisco R&D Campus
Will feature drug discovery, gene and RNA therapy technology
Johnson & Johnson has opened its San Francisco Bay campus, a state-of-the-art research & development facility in the Bay Area, often known as global hub for innovation and entrepreneurship. The nearly 200,000 square-foot facility will be home to up to 400 employees, more than doubling the R&D presence of J&J in that area. The campus connects scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology.
The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies; novel treatments and approaches for retinal and infectious diseases; and advanced data science, including artificial intelligence and machine learning.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop, and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science, and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” says James Merson, PhD, site head, San Francisco Bay campus and global therapeutic area head, infectious diseases, Janssen Research & Development, LLC.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
